



RESEARCH ARTICLE

PHARMACOLOGY

ANTICANCER ACTIVITY OF PETROLEUM ETHER EXTRACT OF *ABRUS PRECATORIUS* ON EHRLICH ASCITIS CARCINOMA IN MICE**¹J. ANBU*, ¹V. RAVICHANDIRAN, ¹M. SUMITHRA, ¹B. SUDHEER CHOWDARY, ¹K. SWAROOP KUMAR.S.L.V.V.S.N, ¹R. KANNADHASAN AND ²R. SATHEESH KUMAR.**¹Department of Pharmacology, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai-600117, India²Department of Biochemistry, Vels college of Science, Pallavaram, Chennai-600117. India**J.ANBU**

Department of Pharmacology, School of Pharmaceutical Sciences, Vels University, Pallavaram, Chennai-600117, India.

ABSTRACT

This investigation aims to evaluate the Anti tumour potential of the petroleum ether extract of *Abrus precatorius Linn* (PEEAP) on Ehrlich Ascitis Carcinoma (EAC) tumour model. Tumour was induced in mice by intraperitoneal injection of EAC cells (1×10^6 cells/mouse). PEEAP was administered to the experimental animals at the dose levels of 250, 500 and 1000 mg/kg per day after 24 hrs of tumour inoculation. The anti tumour effect of PEEAP was evaluated by assessing and body weight, survival time, haematological parameters. Oral administration of PEEAP increased the survival time of the EAC bearing mice. The PEEAP brought back the alter levels of the haematological parameters in a dose dependent manner in EAC bearing mice. The results were comparable to that of the result obtained from the animals treated with the standard drug 5-flurouracil (20mg/kg .b.w). Thus present study revealed that PEEAP possessed significant anti tumour activity.



KEY WORDS

Abrus precatorius, Ehrlich Ascitis Carcinoma, Hematological parameters, Tumour growth response.

INTRODUCTION

Drug discovery from the medicinal plants has played an important role in the treatment of cancer and indeed, most new clinical applications of plants secondary metabolites and their derivatives over the last half-century have been made towards combating cancer¹. *Abrus precatorius* (Fabaceae) is a woody climber distributed widely throughout India^{2, 3}. The plant is traditionally used for the treatment of sore tongue and it also has diaphoretic action. This study was undertaken to evaluate the anti tumour potential of the petroleum ether extract of *Abrus precatorius* Linn (PEEAP) against the Ehrlich Ascitis Carcinoma (EAC) tumour model.

MATERIALS AND METHODS

(i) Plant collection:

Abrus precatorius seeds were collected in and around Chennai in the month of June 2009 and authenticated by Dr. Jayaraman, Botanical Survey of India, Chennai, Tamil Nadu, India.

(ii) Preparation of Petroleum ether Extract:

The plant material was shade dried and pulverized. Petroleum Ether extract of the coarsely powdered material was prepared employing Maceration with 2,500 ml of Petroleum ether (RFCL Limited) for 72 h and the extract was concentrated to 8gm. The extract was dissolved in Carboxy methyl cellulose (2%) (Loba chemie Pvt. Ltd) before administration.

(iii) Animals:

Adult Swiss male albino mice (20-25gm) were procured from animal house,

Department of pharmacology, Vels University, and used throughout the study. They were housed in micro lane boxes in a controlled environment (temperature 25±2°C and 12 h dark and light cycle) with standard diet and water *ad libitum*. The study was conducted after obtaining institutional animal ethical committee clearance. (290/CPCSEA/2009-PH/PCOL-07).

(iv) Cancer cell line:

EAC cells were obtained through the courtesy of Amala Cancer Research Center, Thrissur. They were maintained by weekly intraperitoneal inoculation of 10⁶ cells/mouse.⁴

(v) Effect of PEEAP on tumour growth response:

Animals were inoculated with 2×10⁶ cells / mouse on day '0' and treatment with PEEAP started 24 h after inoculation, at a dose of 250,500,1000mg/kg/day, p.o. All the treatments were given for 10 days. The mean survival time (MST) of each group, consisting of 6 mice was noted. The anti tumour efficacy of PEEAP was compared with that of 5-fluorouracil 20 mg/kg/day, i.p for 10 days). Mean survival time and increased life span (%ILS) was calculated using the following equation.^{5, 6}

MST= (Day of first death+day of last death)/2

ILS (%) = [(Mean survival time of treated group / mean survival time of control group)-1] ×100

**(vi) Anti-tumour activity:**

Male Swiss albino mice were divided into 6 groups (n=6). All the groups were injected with EAC cells (0.2ml of 2×10^6 cells /mouse) intraperitoneal⁷. This was taken as day zero.

Group I- Disease control, EAC cell line (2×10^6 cell mouse).

Group II - EAC cell line (2×10^6 cells) treated with 250 mg /kg p.o. of PEEAP.

Group III -EAC cell line (2×10^6 cells) treated with 500 mg /kg p.o. of PEEAP.

Group IV -EAC cell line (2×10^6 cells) treated with 1000 mg /kg p.o. of PEEAP.

Group V - EAC cell line (2×10^6 cells) treated with standard [5-Flurouracil (20 mg/kg i.p.)]

After 10 days of treatment, animals from each group were sacrificed by retro orbital plexus method to evaluate the anti tumour potential of PEEAP.

(vii) Haematological studies:

Haemoglobin content, Red blood cells count (RBC), White blood cells count (WBC) and Packed cell volume (PCV) were measured from freely flowing tail vein blood from all the groups.^{8, 9}

(viii) Statistical analysis:

All the values were expressed as mean \pm SEM. The data were statistically analyzed by one-way ANOVA followed by Dunnett's test. The data of haematological parameters were analyzed using ANOVA followed by Dunnet T-test. P values < 0.05 were considered significant.

RESULTS

Preliminary phytochemical screening of PEEAP was carried out for the detection of phytoconstituents using standard chemical tests. Flavonoids, Alkaloids, tannins, phenolic compounds, saponins, triterpenoids detected in PEEAP. Oral administration of PEEAP increased the mean survival time of EAC bearing mice. In the EAC control group the mean survival time was 18.16 ± 0.4773 , while it increased to 20.5 ± 0.6009 (250mg/kg), 20.33 ± 0.4944 (500mg/kg) and 21.166 ± 0.6009 (1000mg/kg) respectively in PEEAP treated groups. The group treated with standard 5-FU (20mg/kg) showed 24.5 ± 0.4282 for the same. The percentage increase in survivals, it was found to be 11.01%, 11.94%, 16.51% respectively as compared to control group which are represented in Table-1. The EAC bearing mice treated with the PEEAP showed excellent increase in life span when compared to control. Treatment with PEEAP at the doses of 250, 500 and 1000mg/kg reduced the body weight^{10, 11}, PCV^{12, 13} and viable tumour cell count as compared to that of EAC control group and increased the haemoglobin content and RBC count towards normal level. Administration of PEEAP at the doses of 250, 500 and 1000mg/kg in EAC bearing mice reduced the WBC count as compared with the control. Treatment with PEEAP at different doses changed these altered parameters towards normal levels Table-2.

Table-1
Effect of PEEAP treatment on the survival of tumour-bearing mice

Treatment	MST (d)	Increase in Life Span (%)	Body weight
Tumour control	18.16 ± 0.4773	-----	37.45 ± 0.86
5-FU (20 mg /kg, i.p.)	24.5 ± 0.4282	34.9	25.15 ± 0.65
PEEAP (250 mg/kg, p.o.)	20.16 ± 0.6009 **#	11.01	27.5 ± 0.60 **##
PEEAP (500 mg/kg, p.o.)	20.33 ± 0.4944 **#	11.94	30.5 ± 0.44 **##
PEEAP (1000 mg/kg, p.o.)	21.166 ± 0.6009 **##	16.51	29.66 ± 0.45 **##

Control $V_s T$ ** $P < 0.01$, * $P < 0.05$; Standard $V_s T$ ## $P < 0.01$, # $P < 0.05$

Data was analysed by one way ANOVA followed by Dunnet's 't' test, n=6

This article can be downloaded from www.ijpbs.net




Table-2
Effect of PEEAP extract on hematological parameters of cancer (EAC) bearing mice


Treatment	Hb (g%)	RBC(million/mm ³)	WBC(10 ³ cells/mm ³)	PCV (mm)
Tumour bearing	6.3166±0.1740	3.95±0.1088	18.3±0.0695	21.81±0.454
5-FU(20mg/kg,i.p.)	11.865±0.0838	3.55±0.119	11.343±0.060	31.63±0.245
PEEAP(250mg/kg)	12.23±0.1406**	12.183±0.1537**##	4.041±0.1003**##	38.11±0.192**##
PEEAP(500mg/kg)	11.83±0.1116**	11.833±0.116**##	14.23±0.049**	32.86±0.619**##
PEEAP(1000mg/Kg)	9.35±0.1360**##	9.35±0.1360**##	13.08±0.087**##	28.73±0.1944**##

Control Vs T **P<0.01, *P<0.05; Standard Vs T ##P<0.01, # P<0.05
Data was analysed by one way ANOVA followed by Dunnet's 't' test, n=6

Graph-1
Effect of PEEAP treatment on the survival of tumour-bearing mice



Graph-2
Effect of PEEAP extract on hematological parameters of cancer (EAC) bearing mice





CYTOLOGICAL STUDIES – EAC




Fig 1




Fig 2




Fig 3



Fig 4

Fig 1 Tumour Control
The cells are larger in size and showed binucleation

Fig 2. PEEAP (250mg/kg)
The cells showed high n/c ratio, plasmacytoid feature with varying degree of degeneration and cytoplasmic vacuolation which is characteristic of immunoblast.

Fig 3. PEEAP (500mg/kg)
The cells showed, plasmacytoid feature with varying degree of degeneration and cytoplasmic vacuolation which is characteristic of immunoblast.

Fig 4, PEEAP (1000 mg/kg)
The cells showed high, plasmacytoid feature with varying degree of degeneration and cytoplasmic vacuolation which is characteristic of immunoblast.



DISCUSSION

Flavonoids have been shown to possess antimalignant effects^{14, 15}. Further more, flavonoids have a chemopreventive role in cancer through their effects on signal transduction in cell proliferation¹⁶ and angiogenesis.¹⁷ Quercetin a well-known bioflavonoid is commonly found in human diet. This flavonoid along with Genistein gained much attention during the last few years as a potential anticancer drug¹⁸. The PEEAP is rich in flavonoids, alkaloids and terpenoids. The cytotoxic and antitumour properties of the extract may be due to these compounds. The present study points to the potential anticancer activity of *Abrus precatorius*. Further studies to isolate, characterize the active principles and elucidate the mechanism of the action of *Abrus precatorius* are in progress. The reliable criteria for judging the value of any anticancer drug are prolongation of lifespan and decrease of tumour volume and viable tumour cell count and increase of non-viable tumour cell count. The results of the present study show an antitumour effect of PEEAP against EAC cells in Swiss albino mice. The present study reveals that PEEAP treatment at the dose level of 250, 500 and 1000 mg/kg b.w are quite effective against Ehrlich ascites carcinoma cells, depicting increase in life span by about 11.01%, 11.94% and 16.51% respectively as compared with control. This substantiates its antitumour properties. Herbal medicine derived from plant extracts are being increasingly utilized to treat a wide variety of clinical diseases, though relatively little knowledge about their mode of action is available. There is a growing interest in the pharmacological evaluation of various plants used in Indian traditional system of medicine.

Plant derived natural products such as flavonoids, terpenoids and steroids etc have received considerable attention in recent years

due to their diverse pharmacological properties including antioxidant and anticancer activity. There has been growing interest in the analysis of certain flavonoids, triterpenoids and steroids due to their potential benefits to human health. One of their main properties in this regard is their antioxidant activity, which enables them to attenuate the development of tumour and inflammatory disease. Antioxidant plays an important role in inhibiting and scavenging radicals, thus providing protection to human against infection and degenerative diseases.

Plants have been prime source of highly effective conventional drugs for the treatment of many forms of cancer, and while the actual compounds isolated from the plant frequently may not serve as the drugs, they provides lead for the development of potential novel agents. Myelosuppression is a frequent and major complication of cancer chemotherapy. Compared to the EAC control animals, PEEAP treatment showed significant tumour inhibition resulted in appreciable improvement in hemoglobin content and RBC count. These observations assume great significance as anemia is a common complication in cancer and the situation aggravates further during chemotherapy since a majority of antineoplastic agents exert suppressive effects on erythropoiesis and thereby limiting the use of drugs.

ACKNOWLEDGEMENTS

The authors express their thanks to Dr. Jayaraman, Botanical Survey of India, Chennai for authentication of the plant material. The authors also wish to thank, Dr. Ishari. K. Ganesh, Chancellor, Vels University for providing the facilities necessary to carry out this research work.



REFERENCES

1. Newman DJ, Cragg GM, Snader KM, Natural Products as sources of new drugs over the period 1981 – 2002. *J. Nat. Prod.*, 66 (7): 1022 – 1037. (2003)
2. Ranju spal, Arahara sivakumar G, kundlik, girhe punje, ashutosh upadhyay, *Invitro* anti oxidative activity of phenolic flavonoid compounds extracted from *abrus precatorius*, *International journal of pharmaceutical sciences*, 1(2):136-140,(2009).
3. Bhardwaj DK, Basht MS, Mehta CK, Flavonoids from *Abrus precatorius*, 19:2040 -2041. (1980).
4. Balasubramanian Raj Kapoor, Marmuthusankari, Mohansumitra, Jayaraman Anbu, Narayanaswami HariKrishnan, Manavalan Gobinath, Venkatesan Suba, Ramachandran Balaji, Anti tumor activity and cytotoxic effect of *phyllanthus Polyphyllus* on Ehrlich ascites carcinoma and human cancer cell, *Journal of Bio science, Biotechnology, Biochemistry*, 71(9): 2177 - 2183, (2007).
5. Mazumder UK, Gupta M, Maiti S, Mukherjee M, Anti-tumor activity of *Hygrophilaspinoso* on Ehrlich ascites carcinoma and sarcoma – 180 induced mice, *Indian Journal of Experimental Biology*, 35: 473 – 477,(1997).
6. Gupta M, Mazumder UK, Rath N, Mukhopadhyay DK. Anti-tumor activity of methanolic extract of *Cassia fistula L.* seed against Ehrlich ascites carcinoma. *Journal of . Ethnopharmacology*, 72: 151 – 156,(2000).
7. Gupta M, Mazumder UK, Sambath Kumar R, Siva Kumar T, Mohan vamsi ML. Anti-tumor activity and antioxidant status of *Caesalpinia bonducella* Against Ehrlich ascites carcinoma in Swiss Albino mice. *Journal of Pharmacological Sciences*, 94: 177 – 184. (2004).
8. Pradhan D, Panda PK, Tripathy G, Pharmacological Evaluation of *S.trifoliatius* fruit extract of the plant *S.trifoliatius* in Ehrlich Ascites Carcinoma (EAC) tumor bearing mice, *International Journal of Toxicological and Pharmacological Research*, 1(2); 44-46. (2010)
9. Malaya Gupta, Upal K.anti Mazumder, Pallab K. Haldar, Chandi C. Kandar,Laxmanan Manikandan and Senthile GP, Anticancer Activity of *Indigofer aspalathoides* and *Wedelia calendulaceae* in Swiss Albino Mice, *Iranian Journal of Pharmaceutical Research*, 6 (2): 141-145,(2009).
10. Ahmed H, Chatterjee BP, Debnath AK, Interaction and *in vivo* growth inhibition of Ehrlich ascites tumor cells by jacalin, *Journal of Biosciences*,13(4): 419–424, (1988).
11. Santoshkumar H Dongre, Shrishailappa Badami, Senthilkumar Natesan, Raghu Chandrashekhar H, Antitumor Activity of the Methanol Extract of *Hypericum hookerianum* Stem Against Ehrlich Ascites Carcinoma in Swiss Albino Mice, *Journal of Pharmacological Sciences*, 103: 354 – 359, (2007).
12. Nargish begum T, Muhammad Ilyas MH, Kalavathy S, Vijayaanand A, Samath kumar P, Santhil R ,Effects of ethanolic leaf extract *azima tetraacantha* on ehrlich ascites carcinoma tumor bearing mice, *Research journal of medicine and medical sciences*, 4(2): 351-354, (2009).
13. Subba reddy VV, Sirsi M, Cytotoxic activity against Ehrlich carcinoma and human k 562 lukeamia of alkaloids and flavonoid from two *solanum* species, *Journal of brazilian chemical society*, 13(6): 838-842, (2002).
14. Brown J P, A review of the genetic effect of naturally occurring flavonoids,



- anthraquinones and related compounds, *Mutation Research*, 75: 243-247, (1980).
15. Hirano T, Oka K, Akiba M, Antiproliferative effect of synthetic and naturally occurring flavonoids on tumor cells of human breast carcinoma cell lines, ZR-75-1, *Research in Community Pathology and Pharmacology*, 64: 69-78, (1989).
 16. Weber G, Shen F, Prajda N, Yeh Y A, Yang H, Increased signal transduction activity and down regulation in human cancer cells, *Anticancer Research*, 16: 3271-3282, (1996).
 17. Fotsis T, Pepper M S, Aktas E, Breit S, Rasku S, Adlercreutz H, Flavonoids, dietary-derived, inhibitors of cell proliferation and in vitro angiogenesis, *Cancer Research*, 57: 2916-2921: (1997).
 18. Indap M A, Bhosle S C, Shinde A D, Barkume M S, Ingle A D, Tumour response of quercetin, a flavonoid with some promises in therapies, *Indian journal of pharmaceutical sciences*, 68(5), 570-574, (2006).